<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="284">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157451</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00022029</org_study_id>
    <secondary_id>NCI-2021-11880</secondary_id>
    <secondary_id>STUDY00022029</secondary_id>
    <nct_id>NCT05157451</nct_id>
  </id_info>
  <brief_title>Y-90 Versus SBRT for Inoperable HCC</brief_title>
  <official_title>Randomized Prospective Two-Arm Feasibility Trial of Stereotactic Body Radiation Therapy Versus Yttrium-90 Segmentectomy in Inoperable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Foundation, Oregon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiological Society of North America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial tests whether Y-90 segmentectomy (internal radiation) versus stereotactic&#xD;
      body radiation therapy (external radiation) is more optimal in treating inoperable liver&#xD;
      cancer. Y-90 segmentectomy consists into very tiny radioactive glass beads that can be&#xD;
      injected into the liver through the blood vessels supplying the liver. Stereotactic body&#xD;
      radiation therapy uses special equipment to position a patient and deliver external radiation&#xD;
      to tumors with high precision. This study many help doctors determine which treatment, Y-90&#xD;
      segmentectomy or SBRT, works better in treating liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine feasibility of trial enrollment (enrollment date).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess differences in overall survival, local control, time to intrahepatic&#xD;
      progression, time to next treatment, rate of liver transplant, toxicity, and patient reported&#xD;
      complications and quality of life.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Compare cumulative cost of treatment-related medical care at 13 months.&#xD;
&#xD;
      OUTLINE: Patients will be randomized in 1 of 2 arms.&#xD;
&#xD;
      Arm I: Patients undergo SBRT every other day for a total of 5 days over 2 weeks.&#xD;
&#xD;
      Arm II: Patients receive Y-90 radioembolization via injection on day 1.&#xD;
&#xD;
      After completion of study, patients are followed up at 2, 4, and 12 weeks and then every 3&#xD;
      months for 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">January 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of enrollment (enrollment rate)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Determine feasibility of trial enrollment for two therapeutic groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Death, adjuvant systemic therapy or liver directed therapy to treated lesion, transplant, lost to follow up, or 13 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time of radiographic evidence of treated tumor progression as determined by tumor board review, adjuvant systemic therapy or liver directed therapy to treated lesion, transplant, death, or 13 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intrahepatic progression</measure>
    <time_frame>Time of radiographic intrahepatic progression, adjuvant systemic therapy or liver directed therapy, transplant, death, or 13 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of liver transplant</measure>
    <time_frame>Time of liver transplant, death, or 13 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-classic radiation induced liver disease</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Defined as a Child-Pugh criteria &gt;= 2 point increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patient reported outcome-Common Terminology Criteria for Adverse Events</measure>
    <time_frame>Baseline up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported quality of life</measure>
    <time_frame>Baseline to 13 months</time_frame>
    <description>Measured by Functional Assessment of Cancer Therapy-Hepatobilliary Cancer compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>Time to next liver directed or non-adjuvant systemic therapy, transplant, or death, assessed up to 13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Stage I Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage II Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage III Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT every other day for a total of 5 days over 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Y-90 radioembolization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Y-90 radioembolization via injection on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (SBRT)</arm_group_label>
    <arm_group_label>Arm II (Y-90 radioembolization)</arm_group_label>
    <other_name>QOL</other_name>
    <other_name>quality of life (QoL)</other_name>
    <other_name>Quality-of-Life</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (SBRT)</arm_group_label>
    <arm_group_label>Arm II (Y-90 radioembolization)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Arm I (SBRT)</arm_group_label>
    <other_name>SABR</other_name>
    <other_name>SBRT</other_name>
    <other_name>Stereotactic Ablative Body Radiation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Yttrium-90 Microsphere Radioembolization</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm II (Y-90 radioembolization)</arm_group_label>
    <other_name>Yttrium Y 90 Microsphere Therapy</other_name>
    <other_name>Yttrium-90 Radioembolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Age &gt;= 18 years at time of informed consent. Both men and women and members of all&#xD;
             races and ethnic groups will be included.&#xD;
&#xD;
          -  Patient with non-metastatic hepatocellular carcinoma (HCC) including lesion(s)&#xD;
             amenable to definitive therapy with either SBRT or Y-90 segmentectomy, limited to =&lt; 2&#xD;
             liver segments, as agreed upon by the multidisciplinary tumor board consensus.&#xD;
&#xD;
          -  Patient not otherwise optimal candidates for resection or thermal ablation, as agreed&#xD;
             upon by the multidisciplinary tumor board.&#xD;
&#xD;
          -  Have a Child-Pugh criteria (CP) score B7 or better.&#xD;
&#xD;
          -  Eastern Clinical Oncology Group (ECOG) performance status =&lt; 1, or Karnofsky&#xD;
             performance scale &gt; 70.&#xD;
&#xD;
          -  No other prior invasive malignancy is allowed except for the following: adequately&#xD;
             treated basal or squamous cell skin cancer, in situ breast or cervical cancer. Stage I&#xD;
             or II invasive cancer treated with a curative intent without evidence of disease&#xD;
             recurrence for at least five years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding, or expecting to conceive children within the&#xD;
             projected duration of the trial, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, serious or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirement, substantially increase risk of incurring adverse&#xD;
             events (AEs) or compromise the ability of the patient to give written informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nima Nabavizadeh</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nima Nabavizadeh</last_name>
      <phone>503-494-8756</phone>
      <email>nabaviza@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Nima Nabavizadeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nima Nabavizadeh</last_name>
      <phone>503-494-8756</phone>
    </contact>
    <investigator>
      <last_name>Nima Nabavizadeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Nima Nabavizadeh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

